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Gatekeepers and Goalposts: 
The Need for a New Regulatory Paradigm for 
Whole Genome Sequence Results 
By Trevor Woodage* 
I. INTRODUCTION 
¶1  The ability to obtain a person’s whole genome sequence for a cost of one thousand 
dollars is nearly here. Many clinicians expect that this will usher in an era of personalized 
medicine by allowing the development of individualized disease-risk profiles, preventive 
medicine strategies, and treatment options. However, it is not clear that the regulatory 
strategy that currently controls the approval and availability of more limited genetic 
tests—typically meant to investigate one or a small number of disease or other traits—
provides a satisfactory framework for whole genome sequence testing. 
¶2  This Perspective takes the position that the generation of whole genome sequence 
testing information needs to be treated differently than the tests and results associated 
with more traditional diagnostic assays. Part I considers the current regulatory 
environment and efforts to reform the oversight of genetic tests, in particular, the solution 
to the question of whether consumers should be permitted to order whole genome 
sequence tests without the guidance of a health-care professional. Part II discusses how 
whole genome sequence tests differ from conventional genetic tests both in the vastly 
greater amount of information that is generated and in the ways the information can be 
interpreted and reinterpreted for different purposes at different times. Part III suggests 
that rather than using the current regulatory approach of concentrating on technical 
attributes of the whole genome sequence testing process, regulatory approaches should be 
directed to the tools needed to analyze and apply deoxyribonucleic acid (DNA) sequence 
information. Such efforts will safeguard patients from adverse outcomes associated with 
unreliable disease-risk prediction, while improving access to the perceived benefits of 
whole genome sequence testing. 
II. BACKGROUND 
¶3  In April 2003, scientists working on the Human Genome Project (HGP) finished a 
thirteen-year effort to sequence the approximately three billion nucleotides that make up 
the human genome.
1
 This haploid genome (representing only one of the two copies that 
each person inherits from his or her parents) was a consensus sequence cobbled together 
 
*
 Attorney, Fish & Richardson, P.C.; Ph.D., University of Sydney; J.D., University of Minnesota Law 
School. Thanks to Susan M. Wolf and Mark S. Ellinger for thoughtful comments. 
1
 See International Consortium Completes Human Genome Project, NAT’L INST. OF HUMAN GENOME 
RESEARCH (Apr. 14, 2003), http://www.genome.gov/11006929. 
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with sequences from DNA samples obtained from several individuals.
2
 The HGP’s 
sequencing cost alone was at least $500 million.
3
 The first individual human genomes 
were sequenced in 2007
4
 at costs ranging from $1.5 million to $100 million.
5
 By mid-
2009, eight people had been sequenced, costing as little as $50,000 per person.
6
 By the 
end of 2010, one company announced that it had sequenced over 800 genomes,
7
 with 
sequencing costs under $10,000 per genome.
8
 In 2011, whole genome sequencing costs 
dropped below $5000,
9
 and consumers could sign up to have all protein-coding regions of 
their genomes sequenced for under $1000.
10
 
¶4  In the face of these dramatic trends, it is not surprising that scientists and 
businessmen propound the widespread availability of the “thousand-dollar genome” and 
claim that personal genome sequencing will herald revolutionary advances in medicine 
and biology.
11
 Much of the excitement about the widespread availability of relatively 
inexpensive whole genome sequence (WGS) data comes from the prospect that the 
sequence information will allow people to create individualized disease-risk profiles and 
take preventative lifestyle measures for improved health.
12
  
¶5  Scientists have used DNA sequence information to diagnose and predict the risk of 
developing disease for decades.
13
  However, they have increasingly applied DNA 
sequence information to understanding common, multifactorial conditions rather than 
rare, single-gene conditions, making risk estimates more often probabilistic than 
 
2
 See Facts About Genome Sequencing, U.S. DEP’T OF ENERGY, OFFICE OF SCI., 
http://www.ornl.gov/sci/techresources/Human_Genome/faq/seqfacts.shtml#whose (last updated Sept. 19, 
2008). 
3
 Nicholas Wade, Technology Lowers Cost of Decoding a Genome to $50,000, N.Y. TIMES, Aug. 11, 
2009, at D3, available at 2009 WLNR 15505816.  
4
 KEVIN DAVIES, THE $1,000 GENOME: THE REVOLUTION IN DNA SEQUENCING AND THE NEW ERA OF 
PERSONALIZED MEDICINE 27–28 (2010) (noting that diploid sequences were produced in 2007 for both J. 
Craig Venter and James Watson, two pioneer scientists involved in DNA sequencing). 
5
 JULIA E. RICHARDS & R. SCOTT HAWLEY, THE HUMAN GENOME: A USER’S GUIDE 443 (3d ed. 2011). 
Individual genome sequencing requires characterization of twice as much DNA as the human reference 
sequence produced by the HGP because a diploid genome—containing the chromosomal DNA inherited 
from each parent—must be sequenced. See Jon Cohen, Venter’s Genome Sheds New Light on Human 
Variation, 317 SCI. 1311, 1311 (2007). 
6
 Wade, supra note 3. 
7
 Press Release, Complete Genomics, Complete Genomics Reports Results for Fourth Quarter and Fiscal 
Year 2010 (Mar. 10, 2011), http://ir.completegenomics.com/releasedetail.cfm/ReleaseID=556147. 
8
 Kevin Davies, The $10,000 Genome and Counting: The Complete Picture for 2011, BIO-IT WORLD 
(Feb. 7, 2011) http://www.bio-itworld.com/news/02/07/11/10000-dollar-genome-Complete-picture-
2011.html. 
9
 Illumina Drops Cost of Whole-Genome Sequencing Services, GENOMEWEB DAILY NEWS (May 9, 
2011), http://www.genomeweb.com/sequencing/illumina-lowers-cost-whole-genome-sequencing-services. 
10
 Exome 80x Pilot Program, 23ANDME.COM, https://www.23andme.com/exome/ (last visited May 27, 
2012); Matthew Herper, The Future Is Now: 23andMe Now Offers All Your Genes for $999, FORBES (Sept. 
27, 2011, 4:55 PM), http://www.forbes.com/sites/matthewherper/2011/09/27/the-future-is-now-23andme-
now-offers-all-your-genes-for-999/. 
11
 See DAVIES, supra note 4, at 9–13. 
12
 See FRANCIS S. COLLINS, THE LANGUAGE OF LIFE: DNA AND THE REVOLUTION IN PERSONALIZED 
MEDICINE 15–17 (2010). 
13
 See generally Stylianos E. Antonarakis, Mutations in Human Diseases: Nature and Consequences, in 
1 EMERY AND RIMOIN’S PRINCIPLES AND PRACTICE OF MEDICAL GENETICS 53–63 (David L. Rimoin ET 
AL. Eds., Pearson Prof’l Ltd 3d ed. 1997) (1983) (discussing a wide variety of mutations that cause disease 
and how genetic variation (genotype) can correlate with clinical outcome (phenotype)). 




 Concerns about how to interpret the results of these new applications fuel a 
hotly contested debate underway concerning the role of government oversight in 
controlling the availability and use of genetic tests.
15
 
III. REGULATORY OVERSIGHT OF GENETIC TESTS 
¶6  Genetic tests can be regulated either as products or services. The Food and Drug 
Administration (FDA) regulates products, however, services are concurrently regulated 
by branches of the U.S. Department of Health and Human Services, including the FDA, 
the Centers for Disease Control and Prevention (CDC), and the Centers for Medicare and 
Medicaid Services (CMS), and sometimes state agencies.
16
 In addition, non-government 
actors including professional and industry organizations can impose other controls on 
genetic testing services.
17
 Also, even if not considered a source of regulations, health 
insurers play a major role in controlling availability and widespread access to genetic 
testing services.
18
 Like health insurance companies, CMS can control access to genetic 
tests through its reimbursement policies.
19
 Understanding the regulatory landscape as it 
relates to WGS testing requires consideration of the authority that agencies have exerted 
over genetic testing to date and recent moves to increase that authority over direct-to-
consumer (DTC) genetic testing. 
A. Federal Agencies and Ambiguity in the Exercise of Agency Authority Over 
Genetic Tests 
¶7  Responding to concerns about the quality of clinical laboratory testing, Congress 





 David Botstein & Neil Risch, Discovering Genotypes Underlying Human Phenotypes: Past Successes 
for Mendelian Disease, Future Approaches for Complex Disease, 33 NATURE GENETICS 228, 232 (2010). 
15
 Compare Letter from Michael D. Maves, Exec. Vice-President & Chief Exec. Officer, Am. Med. 
Ass’n, to Food & Drug Admin. 1 (Feb. 23, 2011), available at http://www.ama-
assn.org/ama1/pub/upload/mm/399/consumer-genetic-testing-letter.pdf [hereinafter AMA letter] 
(requesting that the FDA impose strong oversight measures on genetic tests such that they could not be 
made available to consumers without physician involvement), with Daniel MacArthur, Last Chance: Let 
the FDA Know Why You Want Direct Access to Your Own Genome, WIRED SCIENCE (Apr. 29, 2011, 4:55 
PM), http://www.wired.com/wiredscience/ 2011/04/last-chance-let-the-fda-know-why-you-want-direct-
access-to-your-own-genome/ (arguing for minimal regulation of genetic tests). 
16
 LORI B. ANDREWS ET AL., GENETICS: ETHICS, LAW AND POLICY 310 (3d ed.). This Perspective will 
only consider oversight of genetic testing services. At least in the near-term there is no evidence that stand-
alone WGS products are being developed. Further, even if it was possible to produce a “black box” that 
could completely automate WGS testing, data interpretation issues would remain because of their 
heterogeneous nature. For state controls over genetic testing, see SURVEY OF DIRECT-TO-CONSUMER 
TESTING STATUTES AND REGULATIONS, GENETICS & PUBLIC POLICY CENTER (2007), available at 
http://www.dnapolicy.org/resources/DTCStateLawChart.pdf. This Paper will not discuss state regulation of 
genetic tests. 
17
 See id., at 310. 
18
 See Michelle Andrews, Genetic Tests Abound. Why Won’t Insurers Pay?, N.Y. TIMES, May 19, 2002, 
§ 3, at 39, available at 2002 WLNR 4064237. 
19
 See, e.g., Norm Alster, Diagnostic Testing Firm Carves out Territory Between Behemoths, INVESTORS 
BUS. DAILY, June 24, 2009, available at 2009 WLNR 12002504; Bernadette Tansey, Diagnostic Test 
Could Pinpoint Origin of Cancers, S.F. CHRON., May 8, 2008, at C1, available at 2008 WLNR 8612425.  
20
 Clinical Laboratory Improvements Amendments of 1988, 42 U.S.C. § 263(a) (2006); see also Morton 
K. Schwartz, Genetic Testing and the Clinical Laboratory Improvement Amendments of 1988: Present and 
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 4 
allowed the CMS and CDC to implement standards for laboratory certification, focusing 
on intra-laboratory quality control and quality assurance mechanisms rather than on the 
clinical uses of test results.
21
  
¶8  Under CLIA, genetic testing must meet general testing standards, but there is no 
requirement that genetic tests meet any particular specialty standards, despite their high 
complexity.
22
 Several groups, including the Secretary’s Advisory Committee on Genetic 
Testing;
23
 the Genetic Alliance, a patient advocacy group;
24
 and the American Society of 
Human Genetics,
25
 identified a need and called for the creation of a genetic testing 
specialty under CLIA. However, CMS chose not to create a genetics specialty under 
CLIA, determining that the “slow and painstaking” development of proficiency standards 
would not be able to keep up with the rapid development of new genetic tests.
26
 Given 
CMS’s failure to act, it appeared that any substantive federal regulatory oversight of 
genetic tests would have to come from another agency, such as the FDA. 
¶9  The FDA has statutory authority to regulate drugs and medical devices.27 Medical 
devices include any “instrument, apparatus, implement, machine, contrivance, implant, in 
vitro reagent, or other similar or related article”, which is “intended for use in the 
diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or 
prevention of disease.”
28
 Courts grant the FDA broad discretion in deciding regulatory 
classifications
29




¶10  Diagnostic tests sold to hospitals and commercial laboratories are classified as 
devices by the FDA and must undergo pre-market approval.
31
 But a broad exception has 
been exploited to allow many genetic tests to escape the requirement for that FDA pre-
 
Future, 45 CLINICAL CHEMISTRY 739, 739 (1999). 
21
 See SEC’Y’S ADVISORY COMM. ON GENETIC TESTING, ENHANCING THE OVERSIGHT OF GENETIC 
TESTS: RECOMMENDATIONS OF THE SACGT 9 (2000) [hereinafter SACGT RECOMMENDATIONS], available 
at http://oba.od.nih.gov/oba/sacgt/reports/oversight_report.pdf.The Healthcare Financing Administration 
(HCFA) was renamed as the CMS in 2001. Press Release, Dep’t of Health and Human Servs., The New 
Centers for Medicare & Medicaid Services (CMS) (June 14, 2001), available at 
http://archive.hhs.gov/news/press/2001pres/20010614a.html. 
22
 See Rebecca Antar Novick, Note, One Step at a Time: Ethical Barriers to Home Genetic Testing and 
Why the U.S. Health System Is Not Ready, 11 N.Y.U. J. LEGIS. & PUB. POL’Y 621,627–28 (2008). 
23
 See SACGT RECOMMENDATIONS, supra note 21, at 25–28. 
24
 Press Release, Genetic Alliance, Genetic Alliance Calls for Genetic Testing Specialty Under CLIA 
(Mar. 2, 2006), available at http://www.geneticalliance.org/policy.clia.release. 
25
 Kathy Hudson et al., ASHG Statement on Direct-to-Consumer Genetic Testing in the United States, 81 
AM. J. HUM. GENETICS 635, 637 (2007). 
26
 Novick, supra note 22, at 628 (citing Letter from Dennis G. Smith, Dir., Ctr. for Medicaid & State 
Operations, to Kathy Hudson, Dir., Genetics & Pub. Policy Ctr. (Aug. 15, 2007)). 
27
 PETER BARTON HUTT ET AL., FOOD AND DRUG LAW: CASES AND MATERIALS 29 (3d ed. 2007). 
28
 Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 321(h) (2006); see also Juliana Han, Note, The 
Optimal Scope of FDA Regulation of Genetic Tests: Meeting Challenges and Keeping Promises, 20 HARV. 
J.L. & TECH. 423, 430–34 (2007) (discussing the sources of FDA jurisdiction over genetic tests). 
29
 See United States v. An Article of Drug . . . Bacto-Unidisk . . ., 394 U.S. 784, 798 (1969) (holding that 
the FDA had the authority to determine whether an article should be classified as a drug or a device and 
stating that “remedial legislation such as the Food, Drug, and Cosmetic Act is to be given a liberal 
construction consistent with the Act’s overriding purpose to protect the public health”). 
30
 Gregorio M. Garcia, The FDA and Regulation of Genetic Tests: Building Confidence and Promoting 
Safety, 48 JURIMETRICS J. 217, 218 (2008). 
31
 Douglas A. Grimm, FDA, CLIA, or a “Reasonable Combination of Both”: Toward Increased 
Regulatory Oversight of Genetic Testing, 41 U.S.F. L. REV. 107, 118 (2006). 




 “Home brew” tests use analyte-specific reagents (test reagents 
developed from basic ingredients by the laboratories themselves) that only must comply 
with general controls.
33
 Companies can then avoid the need for pre-market approval by 
allowing end-users to employ home-brew testing.
34
 In July 2007 the FDA moved to 
restrict the breadth of this loophole by issuing a draft guidance document indicating that 




¶11  Although the subject has not explicitly been addressed, it is likely that WGS testing 
would fall squarely within the IVDMIA category. The FDA noted that IVDMIAs are 
tests that are “developed based on observed correlations between multivariate data and 
clinical outcome, such that the clinical validity of the claims is not transparent to patients, 
laboratorians, and clinicians who order these tests.”
36
 Because it comes from so many 
different genes, WGS information is a prototypic example of multivariate data.  Further, 
the clinical validity on which correlations between genotype and phenotype rely is 
definitely not transparent.
37
 The FDA’s rationale for imposing pre-market approval 
requirements in the guidance would also apply to WGS testing: “IVDMIAs frequently 
have a high risk intended use. FDA is concerned that patients and healthcare practitioners 
are relying upon IVDMIAs with high risk intended uses to make critical healthcare 




¶12  If the draft guidance had been implemented, the FDA likely would have regulatory 
authority over WGS testing. But, facing industry resistance, the guidance has not yet been 
adopted.
39
 Instead, the FDA has decided to address DTC genetic testing concerns by 
developing guidance for the broader set of laboratory-developed tests and moving to 





 Id. at 118–19. 
33
 Id. at 119; see also General Controls for Medical Devices, FOOD & DRUG ADMIN., 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/ 
GeneralandSpecialControls/ucm055910.htm (last visited May 28, 2012). 
34
 Andrew Pollack, F.D.A. Asks If a Genetic Test Is Sold Without Approval, N.Y. TIMES, July 18, 2003, 
at C2, available at http://www.nytimes.com/2003/07/18/business/fda-asks-if-a-genetic-test-is-sold-without-
approval.html?pagewanted=all&src=pm (“Companies that develop tests they want to sell to many 
laboratories can take advantage of the home-brew system. Instead of selling a complete test requiring 
F.D.A. approval, they sell the basic ingredients of a test to clinical laboratories. The labs then use the 
ingredients to make home-brew tests. The ingredients, usually chemicals or pieces of DNA, are called 
analyte-specific reagents and are only lightly regulated.”). 
35
 Draft Guidance for Industry and Food and Drug Administration Staff; In Vitro Diagnostic 
Multivariate Index Assays; Availability, 72 Fed. Reg. 41,081 (July 26, 2007). 
36
 Id. at 41,082. 
37
 See infra notes 80-86 and accompanying text. 
38
 72 Fed. Reg. at 41,082. 
39
 See FDA Shelves IVDMIA Regulatory Initiative; Will Focus on Laboratory Developed Tests, LAB 
SOFT NEWS (June 25, 2010, 8:47 AM), http://labsoftnews.typepad.com/lab_soft_news/2010/ 06/fda-
shelves-ivdmia-initiative-will-focus-on-laboratory-developed-tests.html. 
40
 See id. 
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B. The FDA Addresses Direct-to-Consumer Genetic Testing: Is a 
Gatekeeper Necessary? 
¶13  The confluence of the success of the HGP and the rise of the internet as a source of 
information and presence as a commercial marketplace have undoubtedly contributed to 
the proliferation of companies that market and advertise genetic tests directly to 
consumers.
41
 Concerns about DTC genetic testing address two goals that are potentially 
in conflict: personal empowerment
42
 and consumer-protection interests including patient 
safety, accuracy of test results, and freedom from misleading information.
43
 Even strong 
proponents of consumer access to genetic information concede that some government 
oversight is appropriate, including regulations ensuring the accuracy of DNA sequence 
results and the prevention of false claims and unethical advertising.
44
 However, there is a 
substantial amount of disagreement as to whether a healthcare professional should serve 
as an intermediary between the consumer and the genetic test provider.
45
 
¶14  As argued in the previous section, the FDA likely has statutory authority to regulate 
complex genetic tests that are “intended for use in the diagnosis of disease or other 
conditions, or in the cure, mitigation, treatment, or prevention of disease.”
46
 One of the 
central issues in disputes over DTC genetic testing is whether it is intended to diagnose or 
prevent disease.
47
 There is no single answer to this question because DTC genetic testing 










assessment of traits not directly related to disease, such as genetic variants associated 
 
41
 See Direct-to-Consumer Genetic Testing Companies, GENETICS & PUB. POLICY CTR., 
http://www.dnapolicy.org/resources/DTCcompanieslist.pdf (last visited May 28, 2012) (listing thirty-seven 
DTC genetic testing companies as of May 2009); Andrew Polack, A Genetic Test that Very Few Need, 
Marketed to the Masses, N.Y. TIMES, Sept. 11, 2007, at C3, available at 
http://www.nytimes.com/2007/09/11/business/media/11genetics.html (noting concerns that advertising of 
genetic tests for breast cancer mutation screening direct to consumers could result in inappropriate test 
utilization). 
42
 Novick, supra note 22, at 641. 
43
 Sivan Tamir, Direct-to-Consumer Genetic Testing: Ethical-Legal Perspectives and Practical 
Considerations, 18 MED. L. REV. 213, 214 (2010). 
44
 See MacArthur, supra note 15. 
45
 See supra note 15; see also Gaia Bernstein, Direct-to-Consumer Genetic Testing: Gatekeeping the 
Production of Genetic Information, 79 UMKC L. REV. 283, 287–91 (2010); Cynthia Marietta & Amy L. 
McGuire, Direct-to-Consumer Genetic Testing: Is It the Practice of Medicine?, 37 J.L. MED. & ETHICS 
369, 373 (2009). 
46
 Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 321(h) (2006); see also supra notes 27–35 and 
accompanying text of this Perspective. 
47
 See Marietta & McGuire, supra note 45, at 369 (arguing that for multiplex genetic tests “[t]he variety 
of genetic information tested for complicates the issue of whether [DTC genetic testing] companies are 
providing information for recreational purposes only or whether they are also providing medical diagnostic 
information”). 
48
 See, e.g., DNA Testing and Home DNA Test Services, EASY-DNA.COM, http://www.easy-dna.com 
(last visited July 15, 2012); Home DNA and Paternity Tests, THE GENETIC TESTING LABORATORIES, INC., 
http://www.gtldna.com (last visited July 15, 2012). 
49
Andrea Mechanick Braverman, How the Internet Is Reshaping Assisted Reproduction: From Donor 
Offspring Registries to Direct-to-Consumer Genetic Testing, 11 MINN. J.L. SCI. & TECH. 477, 494 (2010). 
50
 See, e.g., ANCESTRYBYDNA, http://www.ancestrybydna.com (last visited July 15, 2012); 
FAMILYTREEDNA, http://www.familytreedna.com (last visited May 28, 2012). 
51
 See, e.g., GENEPARTNER, http://www.genepartner.com (last visited July 15, 2012). 
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and those directed at assessment of disease risk.
55
 Whatever the quality of the science 
underlying these commercial offerings, at least some of the tests, including those for 
genealogical typing and paternity testing, would not seem to fall under FDA jurisdiction, 
unlike tests intended for the diagnosis or prevention of disease.  
¶15  Consistent with the likelihood that not all genetic tests would fall under the FDA’s 
jurisdiction, the FDA may be moving toward a risk-based classification of genetic tests, 
requiring higher standards of oversight for tests that pose higher risks to consumers.
56
 
During a March 2011 meeting, the FDA’s Molecular and Clinical Genetics Panel of the 
Medical Devices Advisory Committee planned to discuss “the benefits and risks of direct 




¶16  While it might be feasible to determine the FDA’s jurisdiction over assays 
involving specific genes or DNA sequence variants and particular intended uses, it is 
more difficult to know if the FDA can regulate tests that analyze a large number of 
genetic variants for various purposes. Several companies now offer DTC genetic testing 
of panels of up to one million or more sequence variants.
58
 For example, 23andMe 
analyzes its test results to return information relating to ancestry and health.
59
 The 
company’s website sends conflicting messages about whether the results have medical 
significance: “Your 23andMe results can help you and your doctor make more informed 
decisions about your healthcare,”
60
 and “[t]he information on this page is intended for 
research and educational purposes only, and is not for diagnostic use.”
61
 In fact, the FDA 
has a settled definition for the term “intended use.” The FDA seeks to determine the 
“objective intent” of the manufacturer by examining labeling claims or advertising matter 
 
52
 See, e.g., INHERENT HEALTH, http://www.inherenthealth.com (last visited July 15, 2012). 
53
 See, e.g., Drug Response: Genetic Differences Often Determine Drug Benefits—and Adverse Events!, 
MATRIX GENOMICS, http://www.matrixgenomics.com/drug-response.php (last visited July 15, 2012). 
54
 See, e.g., Optimum Athletic Performance DNA Analysis—Athletic Analysis & Sports Genetic Test, 
CYGENEDIRECT, http://cygene.infinityarts.com/browse-10873/Optimum-Athletic-Performance-Dna-
Analysis.html (last visited July 15, 2012). 
55
 See, e.g., ENTEROLAB, https://www.enterolab.com (last visited July 15, 2012); Inherited Level of Risk: 
DNA-Based Evaluations for Common Disorders, MATRIXGENOMICS, http://matrixgenomics.com/inherited-
predisposition.php (last visited July 15, 2012). 
56
 See FDA Panel Gets Varied Opinions on DTC Genomics, GENOMEWEB DAILY NEWS (Mar. 10, 
2011), http://www.genomeweb.com/dxpgx/fda-panel-gets-varied-opinions-dtc-genomics (“FDA has been 
considering the possibility of regulating tests in different categories based on risk and benefits, including 
categories such as genetic carrier screening for hereditary diseases, tests which predict risk of future 
diseases, and pharmacogenomic tests that predicting patient response to specific drugs.”). 
57
 Molecular & Clinical Genetics Panel of the Med. Devices Advisory Comm., Meeting Notice, 76 Fed. 
Reg. 6623, 6624 (Feb. 7, 2011). 
58
 See, e.g., 23ANDME, https://www.23andme.com (last visited July 18, 2012); DECODEME, 
http://www.decodeme.com (last visited  July 18, 2012); NAVIGENICS, http://www.navigenics.com (last 
visited July 18, 2012).  
59
 See 23ANDME, supra note 58. 
60
 Why Should You Know Your Genetic Risk, 23ANDME, https://www.23andme.com/health/risks/ (last 
visited July 18, 2012). 
61
 Abdominal Aortic Aneurysm—Sample Report, 23ANDME, 
https://www.23andme.com/health/Abdominal-Aortic-Aneurysm/ (last visited July 18, 2012). 
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 8 
and may even use circumstantial evidence to show that something is being “used for a 
purpose for which it is neither labeled nor advertised.”
62
 
¶17  Certainly, the FDA seems to regard many DTC genetic tests as falling within the 
medical device classification because it has sent warning letters to at least twenty 
companies offering genetic testing services, including companies analyzing large 
numbers of sequence variants.
63
 This also suggests that, if the FDA is using a “regulate to 
risk” approach, then the FDA treats multivariate genetic tests with several possible 
applications as belonging to higher-risk classifications. 
¶18  At its March 2011 meeting, the Molecular and Clinical Genetics Panel was 
receptive to the notion that tests imparting clinical information should only be made 





 and professional societies
66
 have supported this position, arguing that orders 
for and interpretation of disease-related genetic tests need professional guidance because 
of the complexity of the tests and the potential vulnerability of patients concerned about 
the specter of serious illnesses.
67
 Critics attack this position for several reasons. Daniel 
MacArthur, a United Kingdom-based geneticist, suggests that the American Medical 
Association’s recommendation that medical professionals act as gatekeepers to the 
interpretation of genetic information arises from self-interest rather than an ability to add 
value for patients.
68
 He notes that the AMA even implicitly admits this by putting 
 
62
 21 C.F.R. § 801.4 (2010); see also HUTT, supra note 27, at 41–42. 
63
 See In Vitro Diagnostics, FOOD & DRUG ADMIN., http://www.fda.gov/MedicalDevices/ 
ProductsandMedicalProcedures/InVitroDiagnostics/default.htm (last visited July 18, 2012) (listing warning 
letters to six genetic testing companies); Letters to Manufacturers Concerning Genetic Tests, FOOD & 
DRUG ADMIN., http://www.fda.gov/MedicalDevices/ 
ProductsandMedicalProcedures/InVitroDiagnostics/ucm219582.htm (last visited July 18, 2012) (listing 
warning letters to a further fourteen genetic testing companies); see also FDA Warns Consumer Genomics 
Firms, Illumina on Selling Unapproved Dx Products, GENOMEWEB DAILY NEWS (June 11, 2010), 
http://www.genomeweb.com/dxpgx/fda-warns-consumer-genomics-firms-illumina-selling-unapproved-dx-
products; More Genetic Test Firms Receive FDA Warnings, GENOMEWEB DAILY NEWS (July 22, 2010), 
http://www.genomeweb.com/dxpgx/ more-genetic-test-firms-receive-fda-warnings.  
64
 See Andrew Zajac, FDA Panel Advises Caution on Personal Genetic Testing, L.A. TIMES, Mar. 9, 
2011, http://articles.latimes.com/2011/mar/09/nation/la-na-genetic-testing-20110309; see also Alex 
Phillippidis, FDA Panel Hearing Suggests Medical Professionals May Play Role in Direct-to-Consumer 
Genetic Testing, GENETIC ENGINEERING & BIOTECHNOLOGY NEWS (Mar. 22, 2011), 
http://www.genengnews .com/analysis-and-insight/fda-panel-hearing-suggests-medical-professionals-may-
play-role-in-direct-to-consumer-testing/77899379/ (“[I]t has become clear that the agency will enact 
regulations under which professionals of some sort will play a role in administering at least the riskier 
consumer DTC tests.”). 
65
 See, e.g., James P. Evans & Jonathan S. Berg, Next-Generation DNA Sequencing, Regulation, and the 
Limits of Paternalism, 306 J. AM. MED. ASS’N 2376, 2377 (2011) (“[W]hole-genome and whole-exome 
sequencing represent an extraordinarily complex amalgam of multiple medical tests that can be at once 
useful, pointless, confusing, or overtly harmful. . . . Harm from casual testing of consumers could be 
attenuated by prudent FDA regulation requiring a professional relationship between a tested individual and 
a qualified ordering clinician not in the employ of the testing laboratory.”); see also Bernstein, supra note 
45, at 283; Marietta & McGuire, supra note 45, at 373. 
66
 See, e.g., AMA letter, supra note 15, at 1; AM. COLL. OF MED. GENETICS, ACMG STATEMENT ON 
DIRECT-TO-CONSUMER GENETIC TESTING 1 (2008), available at http://www.acmg.net/ 
StaticContent/StaticPages/DTC_Statement.pdf. 
67
 See Bernstein, supra note 45, at 288–89; see also Evans & Berg, supra note 65, at 2377 (“[M]edicine 
is, to at least some extent, an inherently paternalistic endeavor simply because of an inevitable asymmetry 
in knowledge and because those who practice medicine are pledged to avoid causing harm.”). 
68
 See Daniel MacArthur, American Medical Association: You Can’t Look at Your Own Genome 
Without Our Supervision, WIRED (Feb. 24, 2011, 6:43 PM),  
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forward an internally inconsistent position, stating: “Without the guidance of a physician, 
genetic counselor, or other genetics specialist, test results could be misinterpreted, risks 
miscalculated, and incorrect health and lifestyle changes pursued,”
69
 while at the same 
time conceding that, “[t]he number of genetic tests available directly to consumers has 
proliferated rapidly, and several studies have reported that physicians find it difficult to 
keep up with the pace of genetic technology.”
70
 There is substantial support for the 
position that there is a shortage of medical professionals that have the experience and 
training to interpret complex genetic tests.
71
 Other opponents of the medical-professional-
as-gatekeeper model maintain that individuals have “property rights” to their genetic 
information and should not be denied access.
72
 
¶19  Despite the argument that consumers should have access to their genetic test results 
without medical professionals acting as intermediaries, the above analysis suggests that 
the FDA has the statutory authority to regulate multivariate genetic tests that yield 
clinical information. Thus, the FDA seems ready to exert that power and require medical 
gatekeepers. However, the FDA does not appear to have considered whether it is 
appropriate to extend that control to the different realm of WGS testing. 
IV. WHOLE GENOME SEQUENCING IS DIFFERENT THAN CONVENTIONAL GENETIC TESTING 
¶20  There are differences between WGS tests and conventional genetic tests. These 
differences go beyond mere quantitative changes in the number of nucleotides being 
analyzed and instead move WGS testing into a qualitatively distinct class. One difference 
is that the data set produced by a WGS test is so much larger than the data set produced 
in the analysis of a single gene or genetic variant. In addition to the challenges related to 
the sheer scale of the data collected, WGS information is inherently more complex than 
limited, single-gene, data sets because of the need to account for interactions between 
sequence variants in different parts of the genome. Another difference is that a WGS 
serves as a “universal” genetic test. Sequencing the genome once yields a complete set of 





 AMA letter, supra note 15, at 1. 
70
 Id. at 3. 
71
 See Catherine Wicklund, GENETICS EDUCATION PIPELINE AND WORKFORCE 25(2008), available at 
http://www.iom.edu/~/media/Files/Activity%20Files/Research/ GenomicBasedResearch/Wicklund.pdf 
(noting the inadequate number of genetic counselors); Shortage of Physician-Geneticists in the United 
States, THE PERSONAL GENOME (Dec. 28, 2007), http://thepersonalgenome.com/2007/12/shortage-of-
geneticists-in-the-united-states/ (noting that there are almost as many astronauts in the world as there are 
certified geneticists that see patients in the United States). 
72
 See Thomas Goetz, Attention California Health Dept.: My DNA Is My Data, WIRED SCIENCE (June 
17, 2008, 9:57 AM), http://www.wired.com/wiredscience/2008/06/attention-calif/ (“This is *my* data, not 
a doctor’s. . . . Regulation should protect me from bodily harm and injury, not from information that’s mine 
to begin with.”); Cf. Dan Vorhaus, Is the Genetics Right Movement Picking up Steam?, GENOMICS LAW 
REPORT (Mar. 16, 2011), http://www.genomicslawreport.com/index.php/2011/03/16/is-the-genetic-rights-
movement-picking-up-steam/ (discussing bills introduced in the Massachusetts and Vermont state 
legislatures that would codify personal property interests in genetic information); For a more general 
discussion of the debate surrounding genetic information as property, see Margaret Everett, The Social Life 
of Genes: Privacy, Property and the New Genetics, 56 SOC. SCI. & MED. 53, 53–55 (2003). 
73
 At least for normal (non-cancerous) cells.See What Is a Genome?, NAT’L CTR. FOR BIOTECHNOLOGY 
INFO., http://www.ncbi.nlm.nih.gov/About/primer/genetics_genome.html (last visited July 18, 2012). 
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divergent interpretations, and types of interpretations, at different times. Policymakers 
should carefully consider the distinctions between conventional genetic testing and WGS 
testing before trying to fit both types of tests into the same regulatory model. 
A. The Scale and Complexity of WGS Information Creates Substantial 
Interpretive Challenges 
¶21  At present, it is impossible for one individual to examine and assess the full 
significance of the entire sequence of a person’s genome without assistance.
74
 Apart from 
the enormous number of nucleotides that need to be examined, it is a major challenge to 
understand the meaning of a DNA sequence. Genome annotation, the process of 
identifying and mapping the functional elements of the genome to particular nucleotide 
sequences, requires the coordinated efforts of many scientists assisted by sophisticated 
computational methods.
75
 Comprehensive genome annotation involves locating and 
identifying the function of a variety of features of a genome including genes,
76
 control 
elements that can influence whether a gene is expressed by a cell,
77
 and regions of 
genome instability.
78
 Importantly, genome annotation has not been a one-time procedure; 
identification of elements has evolved significantly since the production of the first draft 
versions of the human genome sequence.
79
 
¶22  Annotating the genome with disease associations80 is perhaps even more clinically 
important than just identifying the location and nature of functional elements in the 
genome. The identification of genomic sequences associated with disease risk or other 
clinically-relevant phenotypes is a work-in-progress.
81
 Despite considerable progress in 
identifying specific genetic variants that are associated with human disease and other 
clinical phenotypes, most of the underlying heritable factors have not yet been 
identified.
82
 For example, at least seventy-one genetic variants are known to contribute to 
 
74
 If an observer tried to do nothing more than scan the results of a WGS test, at one nucleotide per 
second, it would take approximately 190 years to examine the approximately six billion nucleotides of a 
diploid genome.  
75
 See, e.g., JAMES SHREEVE, THE GENOME WAR: HOW CRAIG VENTER TRIED TO CAPTURE THE CODE OF 
LIFE AND SAVE THE WORLD 298–302 (2004) (describing the process of annotating the fruit fly genome). 
76
 See THE GENE ONTOLOGY, http://www.geneontology.org/ (last visited July 18, 2012)(describing the 
Gene Ontology project, a major bioinformatics initiative). 
77
 The ENCODE Project Consortium, Identification and Analysis of Functional Elements in 1% of the 
Human Genome by the ENCODE Pilot Project, 447 NATURE 799, 804(2007). 
78
 Angela Re et al., Correlated Fragile Site Expression Allows the Identification of Candidate Fragile 
Genes Involved in Immunity and Associated with Carcinogenesis, 7 BMC BIOINFORMATICS 413, at 414-15, 
(2006), available at http://www.biomedcentral.com/content/pdf/1471-2105-7-413.pdf. 
79
 Michael R. Brent, Steady Progress and Recent Breakthroughs in the Accuracy of Automated Genome 
Annotation, 9 NATURE REVS. GENETICS 62, 62 (2008). 
80
 John D. Osborne et al., Annotating the Human Genome with Disease Ontology, 10 BMC GENETICS 
(SUPPL. 1) S6, at S7 (2009), available at http://www.biomedcentral.com/content/pdf/1471-2164-10-S1-
S6.pdf.  
81
 See generally Kalliope Panoutsopoulou & Eleftheria Zeggini, Finding Common Susceptibility 
Variants for Complex Disease: Past, Present and Future, 8 BRIEFINGS IN FUNCTIONAL GENOMICS AND 
PROTEOMICS 345 (2009) (describing progress in the varied techniques used to identify sequence variants 
associated with common clinical outcomes). 
82
 Teri A. Manolio et al., Finding the Missing Heritability of Complex Diseases, 461 NATURE 747, 747–
48 & tbl.1 (2009) (discussing the so-called “missing heritability” of complex disease—that portion of 
population variance in disease frequency that can be attributed to genetic factors—and listing the 
proportion of heritability that has been accounted for to date in several common disease conditions). 
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Crohn’s disease, an inflammatory bowel disease that, at the genetic level, is one of the 
best understood complex diseases.
83
 Even this large number of genetic variants accounts 
for only 23.2% of the known heritability of Crohn’s disease.
84
 The situation becomes 
even more complex when taking into account interactions between genes or other DNA 
sequences that control gene expression
85
 and the effects of different genetic backgrounds 
associated with ethno-geographic ancestry.
86
 
¶23  Genome scientists and bioinformaticians recognize the daunting scale of the 
challenge being posed by the enormous amounts of data being generated by whole 
genome sequencing efforts.
87
 Between July 2007 and July 2011, genome sequencing 
costs declined by a factor of more than 800 while computing costs merely decreased four-
fold.
88
 At present, genome sequence analysis is labor-intensive and requires input from a 
range of fields, including bioinformatics, statistics, and medical genetics. By one 
estimate, the current cost of a comprehensive interpretation of one human genome 
sequence is $285,000.
89
  Other scientists correctly recognize that genome analysis must 
become increasingly automated if we are to avoid being in the position of “$1000 
genome, $1M interpretation,” regardless of whether such estimates are exaggerations.
90
  
¶24  Given the large volume of information generated during a WGS test, the number of 
factors that need to be considered when analyzing that information, and the costs 
associated with that analysis, it is not surprising that sophisticated statistical approaches 
and a range of other computational tools will be needed to interpret WGS results.
91
 A 
number of geneticists are working on algorithms that can be used to predict clinically-
relevant outcomes from WGS results.
92
 With the complexity of analysis needed to 
interpret WGS data, it is reasonable to conclude that even the most experienced medical 
geneticist or genetic counselor, let alone a healthcare professional with no special training 
 
83
 Andre Franke et al., Genome-Wide Meta-Analysis Increases to 71 the Number of Confirmed Crohn’s 
Disease Susceptibility Loci, 42 NATURE GENETICS 1118, 1118 (2010). 
84
 Id. at 1122. 
85
 See, e.g., Lorenzo Beretta, et al., Ability of Epistatic Interactions of Cytokine Single-Nucleotide 
Polymorphisms to Predict Susceptibility to Disease Subsets in Systemic Sclerosis Patients, 59 ARTHRITIS & 
RHEUMATISM 974, 974–75 (2008) (discussing the role of gene-gene interactions in an autoimmune 
disease). 
86
 See, e.g., H.-S. Lee & S.-C. Bae, What Can We Learn from Genetic Studies of Systemic Lupus 
Erythematosis? Implications of Genetic Heterogeneity Among Populations in SLE, 19 LUPUS 1452, 1455–
58 (2010) (discussing the effects of genetic background in Caucasian and Asian patients with lupus). 
87






 Aabha Khemani & Gauri Jaju, Contracting Sequencing Costs Could Mean Ballooning Informatics 
Prices, GENETIC ENG’G & BIOTECHNOLOGY NEWS (May 9, 2012), http://www.genengnews.com/blog-
biotech/contracting-sequencing-costs-could-mean-ballooning-informatics-prices/690/.  
90
 Daniel MacArthur, Genome Interpretation Costs Will Not Spiral Out of Control, GENOMES UNZIPPED 
(May 14, 2012), http://www.genomesunzipped.org/2012/05/genome-interpretation-costs-will-not-spiral-
out-of-control.php.  
91
 Recovery Act Limited Competition for NIH Grants: Research and Research Infrastructure “Grand 
Opportunities” (RC2), NAT’L HUMAN GENOME RESEARCH INST., http://www.genome.gov/27530674#al-2 
(last visited May 28, 2012) (stating that the NIH will fund the development of a range of statistical and 
computational data analysis methods needed to interpret large-scale sequence data). 
92
 See Euan A. Ashley et al., Clinical Assessment Incorporating a Personal Genome, 375 LANCET 1525, 
1526 (2010) (outlining some of the computational approaches being used to identify disease-risk and other 
clinical information based on analysis of WGS data). 
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in genetics, will need computational assistance to be able to interpret WGS data and 
make sound clinical predictions. 
B. Fixed Results and Moving Goalposts: Interpreting and Reinterpreting WGS Data 
¶25  Except for rare, mutations that occur during cell division (and can be the basis for 
cancer) and various sequence rearrangements that may occur during immune system 
responses and brain development, a person’s genomic sequence is fixed from the time of 
conception.
93
 Thus, assuming the WGS test has acceptable technical accuracy, there 
should be no need to sequence a person’s genome more than once. In essence, WGS 
testing is a “universal” test. This conclusion raises questions about who maintains control 
over the genome sequence produced from the WGS test.  
¶26  There are many good reasons why a person would need to have his genomic 
sequence examined more than once in his life. One might be to reanalyze the sequence 
for the same reason that the WGS test was originally performed, but in the light of new 
molecular or clinical information as to the importance of specific genetic variants and 
disease risk. As discussed in the previous section, the amount of information about 
correlations between genotype and phenotype continues to grow,
94
 and it would seem 
prudent to periodically update WGS interpretations in light of that increasing knowledge 
base.
95
 Because the same clinical question would be involved for both the initial 
interpretation and any reinterpretation of the WGS data, it would be reasonable for access 
to and interpretation of that data to be subject to similar regulatory controls. Thus, if the 
FDA decreed that a patient could initially gain access to information regarding clinical 
associations only through a medical professional, then any reinterpretations, too, would 
only be available through a medical professional. It is true that such a requirement could 
pose practical difficulties, such as ensuring that different healthcare professionals had 
access to the WGS data, allowing patients to obtain second opinions and maintain 
continuity of care should they decide to consult different doctors or genetic counselors.  
¶27  A more problematic circumstance would be if, for example, a woman had her 
genome sequenced to help determine whether she was at an elevated risk of developing 
recurring breast cancer and later wanted to examine her genome for clues as to her 
ancestral origin. Would she have to consult her oncologist to gain access to her genomic 
sequence so that she could perform a genealogical analysis? Even though the FDA has 
not shown any interest in trying to regulate genealogy tests, it is possible that the woman 
would have to choose between allowing her healthcare provider to continue acting as a 
genomic gatekeeper or to wastefully order a repeat WGS test.  
¶28  Perhaps still more complex from a regulatory perspective, would be the case of a 
man who first had WGS testing performed for a low-risk indication and subsequently 
decided that he wanted to know if he was at risk for a serious medical condition, such as 
Alzheimer’s disease.
96
 If the regulators decide to place restrictions on ordering a low-risk 
 
93
 See KENNETH M. WEISS, GENETIC VARIATION AND HUMAN DISEASE: PRINCIPLES AND EVOLUTIONARY 
APPROACHES 7-10 (1993). 
94
 See supra notes 80-86 and accompanying text. 
95
 In fact, this practice has already been proposed. Ashley et al., supra note 92, at 1534 (“Since risk 
estimates change as studies are completed, a continually updated pipeline is necessary.”). 
96
 Under this framework, a low-risk indication would be one without serious consequences, such as a 
genetic test to predict hair curliness, while a high-risk indication would be one associated with a serious 
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test and accessing WGS information, then once permission had been granted, it might be 
difficult to prevent access for the later higher-risk indication, which might require a 
genetic gatekeeper. In theory, this scenario could be avoided if the FDA chose to regulate 
WGS testing based on the greatest possible harm that could come to test users through 
misinterpretation,
97
 requiring a medical professional to vet all requests to perform and 
interpret WGS tests, thereby treating all indications for carrying out WGS tests as high-
risk. Regulating all WGS tests as if they were high-risk could lead to undesirable 
outcomes. For one thing, it could impede genetic research. For example, research-
oriented WGS tests could be placed into a high-risk category, simply because clinically-
actionable results might be returned to a study participant.
98
 This could entangle 
researchers in additional regulatory requirements such as mandating the necessity of an 
independent medical professional to order and interpret WGS testing for study subjects. 
However, it is unlikely that the FDA might elect to regulate WGS tests as if they were all 
being performed for high-risk indications. The FDA does not have statutory authority to 
regulate all genetic tests, just those “intended for use in the diagnosis of disease or other 
conditions, or in the cure, mitigation, treatment, or prevention of disease.”
99
 
¶29  Thus, there are appropriate and desirable reasons to allow reinterpretation of WGS 
data for the same or different purposes. But if the primary regulatory focus is on the 
conditions under which the WGS test itself can be performed, there may be difficulties 
either from constraints on access to the genomic sequence by genetic gatekeepers or 
statutory impediments to the FDA exerting control over the WGS testing process. 
V. OVERSIGHT OF CLINICAL WGS TESTING SHOULD PRIMARILY FOCUS ON TOOLS USED 
TO INTERPRET WGS DATA 
¶30  Rapid changes in genetic technologies and the understanding of genetics raise the 
risk that regulatory agencies may feel forced to choose between adhering to outdated 
policies and abandoning oversight in the belief that regulatory targets are changing too 
quickly for effective response. This Perspective suggests that this dilemma could be 
avoided by breaking the issue of regulating WGS testing into more tractable parts. In 
particular, regulatory authorities should separate oversight of technical aspects of WGS 
test performance from the oversight of data interpretation and presentation. 
A. WGS Testing Systems and Services Should be Required to Meet Analytical 
Validity Standards 
¶31  Even opponents of strict regulatory oversight of genetic testing accept that steps 
should be taken to certify the integrity of raw sequencing data.
100
 Ensuring that a test 
 
illness such as Alzheimer’s disease or cancer. 
97
 For instance, underestimating or overestimating disease risk, failing to recognize a disease-causing 
DNA sequence variant, or even arriving at an incorrect diagnosis. 
98
 See Susan M. Wolf et al., Managing Incidental Findings in Human Subjects Research: Analysis and 
Recommendations, 36 J.L. MED. & ETHICS 219,232–36 (2008) (recognizing that there are circumstances 
when it may be appropriate to return incidental findings to research study participants). 
99
 21 U.S.C. § 321(h) (2006); see also supra notes 27-30 and accompanying text. 
100
 E.g., Daniel MacArthur, My Submission to the FDA on the Regulation of Personal Genomics, 
GENETIC FUTURE (May 3, 2011, 8:46 PM), http://www.wired.com/wiredscience/2011/05/my-submission-
to-the-fda-on-the-regulation-of-personal-genomics/. 
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actually measures the characteristic it purports to measure and that it does so accurately 
and reliably is known as analytical validity.
101
 Setting analytical validity standards for 
WGS testing would require consideration of several parts of the data generation process. 
While a detailed consideration of standards for each step of WGS testing is beyond the 
scope of this Perspective, attention would need to be given to both the laboratory and 
informatics procedures employed in the production of WGS data. 
¶32  The types of factors considered in the validation of other genetic testing 
methodologies are well established.
102
 The FDA has already granted regulatory approval 
to DNA sequencing systems for use as diagnostic tests.
103
 While sequencing an entire 
genome is significantly more complex than sequencing a single gene, scientists are 
developing quality metrics to measure the accuracy of sequence calls made by the high-
throughput sequencing techniques used in WGS testing.
104
 The human genome 
sequencing community has a long tradition of paying close attention to quantifying error 
rates and producing sequence data that minimize errors.
105
 Because these error metrics 
can be used to produce error rates for each nucleotide that is sequenced,
106
 error metrics 
are well-suited to estimating the accuracy of clinical sequencing tests that may need to be 
assessed for specific genomic locations.  
¶33  In addition to setting base-calling standards that can help ensure the accurate 
reading of each nucleotide, safeguarding the accuracy of WGS testing will also require 
consideration of the computational algorithms that assemble fragmentary sequence reads 
into continuous genomic sequence.
107
 Computer scientists have put a great deal of work 
into validating genome assembly algorithms.
108
 These efforts could also be leveraged to 
help develop regulatory standards to ensure the analytical validity of the genome 
assembly process. 
¶34  As well as setting technical standards to judge the analytical validity of WGS 
testing, some thought needs to be given to the optimal administrative structure to provide 
 
101
 SACGT RECOMMENDATIONS, supra note 21 at 15. 
102
 Jennifer A. Isler et al., Analytical Validation of Genotyping Assays in the Biomarker Laboratory, 8 
PHARMACOGENOMICS 353, 362 (2007). 
103
 Letter from Jay S. Epstein, Dir., Office of Blood Research & Rev., Ctr. for Biologics Evaluation & 




 Héctor Corrado Bravo & Rafael Irizarry, Model-Based Quality Assessment and Base-Calling for 
Second-Generation Sequencing Data, 66 BIOMETRICS 665, 672–74 (2010) (“Our ultimate motivation for 
this work is to allow downstream analysis in clinical and biological research using second-generation 
sequencing that appropriately quantifies and captures the uncertainty inherent in the sequencing process.”). 
105
 Brent Ewing & Phil Green, Base-Calling of Automated Sequencer Traces Using Phred. II. Error 
Probabilities, 8 GENOME RES. 186, 186, 193 (1998) (noting the ability to achieve error rates of one 
nucleotide in 10,000). 
106
 Id. at 186. 
107
 Current WGS generation involves determination of the sequence of many millions of short sequence 
reads (typically thirty-five to 400 nucleotides long, depending upon the sequencing technology being used). 
The sequence of the whole genome is “assembled” by sophisticated algorithms that identify overlaps 
between the short sequence reads and computationally stitching the entire sequence together much like 
assembling a jigsaw puzzle. Michael C. Schatz et al., Assembly of Large-Genomes Using Second-
Generation Sequencing, 20 GENOME RES. 1165, 1165 (2010). 
108
 Christie Rizk, To Assess Genome Assemblers Steven Salzburg Organizes a Bake-Off, GENOME 
TECHNOLOGY, March 2011, http://www.genomeweb.com/ informatics/assess-genome-assemblers-steven-
salzberg-organizes-bake. 
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this oversight. A reasonable approach would be to have the FDA regulate WGS 
instruments as medical devices, and to regulate laboratories that perform sequencing 
services under CLIA. The FDA has already given marketing approval to DNA 
sequencing machines for more limited genetic testing,
109
 and WGS testing instruments 
should fit within a similar paradigm.
110
 Appropriate oversight of laboratories that perform 
WGS testing services would generally fall under the auspices of CLIA, and many 
laboratories that perform genetic testing already hold themselves out to be CLIA-
certified.
111
 However, CLIA certification currently offers only the most rudimentary 
assurance as to process quality in a WGS-testing laboratory. Because CLIA lacks a 
genetic testing specialty,
112
 it only requires general quality control standards, such as the 
creation of manuals to document laboratory and quality control processes, as well as 
calibration and validation of laboratory instruments.
113
 CLIA has not yet created a genetic 
testing specialty, perhaps because it could not determine how to deal with issues relating 
to clinical interpretation of genetic test results.
114
 Under the system proposed in this 
Perspective, these issues would not be dealt with under CLIA. Instead, a genetic testing 
specialty under CLIA would need only to certify WGS-testing laboratories for attributes 
related to analytical validity, a much more tractable goal. 
B. Computational Tools Used to Clinically Interpret and Present WGS Information 
Should be Validated 
¶35  Assuming issues of analytical validity can be dealt with by the FDA and CLIA as 
proposed above,
115
 the ability to assess WGS test results for clinical validity (i.e., 
accuracy of the test in diagnosing or predicting risk for a health condition)
116
 and clinical 
utility (i.e., identification of outcomes associated with positive and negative test 
results)
117
 will still be necessary. It remains too early to tell whether WGS tests will have 
substantial clinical utility, such as providing information that will spur action to prevent 
illness, reduce morbidity from inappropriate therapeutic interventions, save healthcare 
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 E.g., Press Release, Life Technologies, FDA Grants Clearance for Celera Diagnostics’ ViroSeq HIV-
1 Genotyping System (Dec. 11, 2002), available at http://ir.lifetechnologies.com/ 
releasedetail.cfm?ReleaseID=541494 (noting that FDA approval had been given to an automated DNA 
sequencer as part of an HIV molecular diagnostic system). 
110
 In fact, Jay Flatley, the CEO of Illumina, a manufacturer of high-throughput DNA sequencing 
instruments, is reported to have begun discussions with the FDA to have next-generation sequencing 
instruments approved for medical purposes. Matthew Herper, Can a DNA Sequencer Get FDA Approval?, 
THE MEDICINE SHOW (Feb. 11, 2011, 1:32 PM), http://blogs.forbes.com/matthewherper/2011/02/11/can-a-
dna-sequencer-get-fda-approval/. 
111
 See, e.g., Perlegen’s California Lab Gains CLIA Certification, GENOMEWEB DAILY NEWS (June 5, 
2009), http://www.genomeweb.com/dxpgx/perlegens-california-lab-gains-clia-certification; Reputable 
CLIA Certified Laboratory, EXISTENCE GENETICS, http://www.existencegenetics.com/certifiedlab.html (last 
visited July 19, 2012). 
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 See supra notes 21-26 and accompanying text. 
113
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117
 Id. 
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costs, and so on. Long-term studies that objectively measure the costs and benefits of 
WGS testing will be needed; the CDC has such a program to evaluate genetic tests.
118
 
¶36  Before clinical utility can even be addressed, there must be assurances that WGS 
tests produce clinically valid results. Genetic sequence variants, or sets of sequence 
variants, must be reliably associated with clinical phenotypes. As discussed previously, 
genotype-phenotype associations continue to be discovered and refined.
119
 This evolving 
process will likely continue for decades.
120
  
¶37  The more immediate need is for a WGS test-result user to know whether to pay 
attention to a putative genotype-phenotype correlation. For example, the association 
between increased risk for Alzheimer’s disease and the ε4 variant of the APOE gene has 
been repeatedly confirmed by epidemiological studies
121
 and supported by laboratory 
studies that show how the variant could lead to dementia.
122
 In contrast, follow-up studies 
could not confirm the proposed correlation between several genetic variants and response 
to an expensive recombinant-DNA-based therapy for rheumatoid arthritis.
123
 Indeed, 
there is evidence that the majority of published genetic associations are false positive 
results that do not hold up on replication.
124
 One way to determine which published 
genetic associations are likely to prove reliable is to manually curate them. Some genetic 
testing companies and academic groups have already adopted this approach.
125
 Although 
the FDA or other regulatory agencies may not have the in-house expertise to assess the 
validity of the large number of genetic associations that could be analyzed in WGS 
information,
126
 one solution would be to call on a federal agency with that expertise, such 
as the National Institutes of Health (NIH), to maintain a central, curated database of 
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genetic associations. In fact, the NIH has created a registry of genetic tests
127
 so that a 
wide range of users may “access information about the availability, validity, and 
usefulness of genetic tests.”
128
 It should be possible to extend this initiative so that it also 
reports on the validity of published genetic associations. 
¶38  Not only should the validity of specific genetic associations be assessed, but also it 
is important that WGS test-result users know which genetic associations produced a 
clinical-outcome prediction. Commentators have noticed that disease-risk predictions 
from different DTC genetic testing companies can offer differing risk scores.
129
 The 
explanation for these different predictions partly appears to be that each company based 
its risk scores on different sets of underlying genetic associations.
130
 This problem 
suggests that it is not enough merely to vet the reliability of genetic associations in order 
to assure the clinical validity of WGS interpretation. Rather, it will also be necessary to 
assess the tools used to arrive at risk-prediction scores as well as the underlying data. 
Current approaches to the interpretation of WGS information tend to be very labor 
intensive, requiring extensive human review.
131
 Computational algorithms are already 
being developed to make risk predictions,
132
 and these algorithms will likely be the 
dominant analytical approach in the near future.  
¶39  In addition to algorithms that produce risk scores, there is a need for computational 
tools to present WGS test results in comprehensible formats. These presentation tools 
will need to be able to communicate answers to specific questions (e.g., “what is this 
person’s risk of developing colorectal cancer?”), or prioritize clinically significant 
findings when WGS testing has been performed as a screening test. Because methods will 
be needed to present clinical interpretations to anyone querying genomic sequence, there 
is no reason why display interfaces could not be developed for audiences with varying 
levels of expertise. DTC genetic testing companies already attempt to do this to a certain 
extent by allowing access to several interpretive layers, ranging from graphical 
representations of a person’s disease risk to numerical risk estimates alongside genotype 
data.
133
 Particularly with the increased attention being paid to innovative ways to present 
 
127
 GTR: Genetic Testing Registry, NAT’L CTR. FOR BIOTECHNOLOGY INFO., 
http://www.ncbi.nlm.nih.gov/gtr/ (last visited May 26, 2012). 
128
 Press Release, Nat’l Inst. of Health, NIH Announces Genetic Testing Registry: Database to Fill 
Information Gaps and Serve as Research Resource (Mar. 18, 2010), available at http://www 
.nih.gov/news/health/mar2010/od-18.htm. 
129
 See COLLINS, supra note 12, at xxi (describing the discrepant risk scores for prostate cancer the 
author received from three DTC genetic testing companies); DAVIES, supra note 4, at 149 (describing a 
similar outcome for type 2 diabetes and prostate cancer risk scores). 
130
 See COLLINS, supra note 12, at xxi; DAVIES, supra note 4, at 189. 
131
 See DAVIES, supra note 4, at 223 (stating that in order to understand a subject’s disease risk “[a] 
small army of Stanford physicians exhaustively pored over [his] sequence”). 
132
 See, e.g., Doctor in a Box, CARNEGIE MELLON UNIV., 
http://www.cmu.edu/homepage/health/2012/winter/doctor-in-a-box.shtml (last visited May 26, 2012); Find 
and Classify Phenotypic Correlations for Variations in Whole Genomes, TRAIT-O-MATIC, 
http://snp.med.harvard.edu/ (last visited May 28, 2012); Promethease, SNPEDIA, 
http://www.snpedia.com/index.php/Promethease(last visited May 28, 2012 
133
 Compare Colorectal Cancer—Sample Report: Example Data, 23ANDME, 
https://www.23andme.com/health/Colorectal-Cancer (last visited May 28, 2012) with Colorectal Cancer—
Sample Report: Technical Report, 23ANDME,https://www.23andme.com/health/Colorectal-
Cancer/techreport (May 28, 2012). 





 it should be possible to develop interfaces that can present WGS results 
in ways that are comprehensible to both expert and lay audiences. 
¶40  Shifting attention applied to WGS testing to concentrate on interpretive tools would 
allow regulatory authorities to address questions related to clinical validity of WGS test 
findings. However, there is an issue of how strictly such regulatory oversight could be 
applied. The FDA has statutory authority to regulate computer software intended for use 
in clinical diagnosis.
135
 Even when that software performs independently of an approved 
medical device (in this case the instrument that generates WGS data), the FDA generally 
considers software an accessory when it takes data from that medical device and 
transforms it for presentation to a user.
136
 But the FDA is also prohibited from interfering 
with the practice of medicine,
137
 and the use of genetic test information can be part of 
medical practice.
138
 Once the FDA has granted approval to a drug or device, physicians 
are free to use that drug or device for unapproved purposes when they feel there is a 
medical justification for doing so.
139
 Thus, if the FDA approves software for use in 
interpreting WGS data under some circumstances, it could not interfere with physicians 
using the software in other circumstances. This limitation effectively emasculates 
regulatory control over software, at least so far as use by licensed medical practitioners is 
concerned. 
¶41  Even though the FDA has to date shown little evidence of readiness to embrace 
innovative approaches to regulating WGS data analysis, it did recently unveil an initiative 
to advance regulatory science.
140
  As part of this initiative, the FDA pledged that a 
priority would be to “Stimulate Innovation in Clinical Evaluations & Personalized 
Medicine to Improve Product Development and Patient Outcomes.”
141
  While the report 
generally foresees the need to validate new tools and approaches for personalized 
medicine,
142




¶42  Whichever route it chooses to adopt, another practical and potentially far-reaching 
limitation to the FDA’s jurisdiction over WGS testing is that there is little the Agency 
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could do to prevent people from sending their DNA to off-shore WGS testing 
companies.
144
 Similarly, it would be difficult to stop people from using WGS information 
analysis tools hosted on servers in other countries.
145
 
¶43  The FDA likely has a restricted regulatory scope over WGS interpretive tools 
because of its inability to interfere with the practice of medicine and its lack of 
jurisdiction over off-shore testing and analysis. Therefore, it might be more appropriate 
for the FDA to attempt to encourage the safe and effective use of WGS tests and 
information using a carrot rather than a stick. One way to do this would be to encourage 
improved understanding of genetics among medical professionals and the general 
public.
146
 Another would be to support best practices by giving a “seal-of-approval” to 
WGS data interpretation tools that make responsible use of clinically-validated genetic 
associations, as well as assessing the limits to which users should rely on interpretations 
when making important health-related decisions. Ultimately, both healthcare 
professionals and consumers would benefit if WGS could be integrated with other forms 
of health information so that genetic information could contribute to medical decision-
making. Medical records incorporating genomic information are being introduced into 
clinical practice,
147
 but as of yet no federal agencies have set standards for WGS data-
interpreting tools. Although a full discussion of data repositories for WGS information, 
especially as they might relate to electronic health records, is beyond the scope of this 
Perspective,
148
 entities that regulate and set standards for the storage of WGS information 
will have a powerful influence over how computational tools are used to interpret and 
communicate genomic sequence. 
VI. CONCLUSION 
¶44  It is virtually certain that WGS information soon will become an important and 
useful tool in both clinical diagnosis and preventive healthcare. What is less certain is 
how access to this technology will be controlled and how the clinical utility of WGS 
information will be ensured. This Perspective has argued that individuals will have a 
lifetime interest in the use, interpretation, and reinterpretation of WGS information.  It 
also posits that it does not make sense to limit access to that data by imposing a 
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requirement that healthcare professionals serve as sole gatekeepers controlling whether 
WGS testing can be procured and how and when WGS data can be correlated with 
clinically-important outcomes.  
¶45  The storehouse of knowledge regarding the correlation of DNA sequence variation 
with health-related outcomes will continue to grow for decades. With these moving 
goalposts, people will need to be able to periodically reanalyze their WGS information to 
keep up to date. No one individual, either geneticist or layperson, could analyze the 
results of a WGS test by himself. The implicit requirement for computational algorithms 
to help a user understand WGS information has two important implications. First, these 
algorithms should be tailored to produce results suitable for audiences with varying levels 
of sophistication about genetic information. Healthcare professionals will continue to 
play essential roles in medical decision-making, but there is no need for them to have a 
monopoly over evaluating and appreciating the significance of WGS information. 
Second, federal agencies should pay special attention to maximizing the clinical utility of 
WGS test interpretation. It is important that the FDA continue to regulate instruments and 
kits used in the generation of WGS data and that CLIA provide qualified oversight over 
WGS testing services. But, it is also essential that the FDA and other federal agencies 
make efforts to maximize the safety and efficacy of WGS test interpretation by providing 
guidance as to which interpretive algorithms and underlying genotype-phenotype 
associations are reliable. Whether federal agencies try to control WGS testing by 
regulation or support intelligent application and understanding of WGS test 
interpretations, devoting resources to the consideration of the clinical validity of WGS 
testing will help maximize the expected benefits of whole genome sequencing. 
 
